Results 31 to 40 of about 178 (87)

Influence of MLC901 Alone and with Moderate Exercise on Pain Response Concurrent Due to Stress of Male Mice. [PDF]

open access: yesGalen Med J, 2019
Background: Physical exercise is known to have a positive effect on pain responses induced by stress, while chronic stress causes a negative effect on cognitive abilities. Depending on the type, duration, and intensity of the stressor, it can induce analgesia or hyperalgesia. Furthermore, the beneficial effects of traditional Chinese medicine MLC901 on
Nasehi M   +4 more
europepmc   +4 more sources

Evaluation of Neuroprotective and Neuroregenerative Potential of NeuroAiD™ II(MLC901) in a Rat Model of Kainic Acid-Induced Spinal Cord Injury. [PDF]

open access: yesMol Neurobiol
Abstract Excitotoxic damage caused by high extracellular levels of glutamate in the spinal cord results in neuronal loss and severe locomotor impairment. This study investigates the efficacy of NeuroAiD II (MLC901), an herbal formulation, in promoting nerve regeneration following spinal cord injury (SCI) induced by kainic acid (KA).
Anjum A   +8 more
europepmc   +3 more sources

The potential of MLC901 (NeuroAiD II™), a traditional Chinese medicine

open access: yesNeuroscience Research Notes, 2019
Stroke, also known as cerebral ischemia, is a common neurological disease. The therapeutic potential of MLC901 (NeuroAiD II™) has been reported in clinical trials on traumatic brain injury as well as in animal and cell models. MLC901 reduced the infarction size, ischemia-induced neurological deficits and pro-inflammatory infiltration of phagocyte.
Suhua Huang   +4 more
openaire   +2 more sources

Alzheimer's disease drug development pipeline: 2019

open access: yesAlzheimer's &Dementia: Translational Research &Clinical Interventions, Volume 5, Issue 1, Page 272-293, 2019., 2019
Abstract Introduction Alzheimer's disease (AD) has few available treatments, and there is a high rate of failure in AD drug development programs. Study of the AD drug development pipeline can provide insight into the evolution of drug development and how best to optimize development practices.
Jeffrey Cummings   +4 more
wiley   +1 more source

MLC901 for Moderate to Severe Traumatic Brain Injury: Pilot, Randomized, Double-Masked, Placebo- Controlled Trial [PDF]

open access: yesOpen Access Journal of Complementary & Alternative Medicine, 2020
Traumatic brain injury (TBI) has significant morbidity, mortality and is the major cause of disability in individuals younger than 35...
openaire   +1 more source

Alzheimer's disease drug development pipeline: 2018

open access: yesAlzheimer's &Dementia: Translational Research &Clinical Interventions, Volume 4, Issue 1, Page 195-214, 2018., 2018
Abstract Introduction Treatments for Alzheimer's disease (AD) are needed due to the growing number of individuals with preclinical, prodromal, and dementia forms of AD. Drug development for AD therapies can be examined by inspecting the drug development pipeline as represented on clinicaltrials.gov. Methods Clinicaltrials.gov was assessed as of January
Jeffrey Cummings   +3 more
wiley   +1 more source

The Effects of Chunghyul‐Dan, an Agent of Korean Medicine, on a Mouse Model of Traumatic Brain Injury

open access: yesEvidence-Based Complementary and Alternative Medicine, Volume 2017, Issue 1, 2017., 2017
Chunghyul‐Dan (CHD) is the first choice agent for the prevention and treatment of stroke at the Kyung Hee Medical Hospital. To date, CHD has been reported to have beneficial effects on brain disease in animals and humans, along with antioxidative and anti‐inflammatory effects.
Won-Woo Choi   +7 more
wiley   +1 more source

Safety and Efficacy of MLC601 in Iranian Patients after Stroke: A Double‐Blind, Placebo‐Controlled Clinical Trial

open access: yesStroke Research and Treatment, Volume 2011, Issue 1, 2011., 2011
Objective. To investigate the safety and efficacy of MLC601 (NeuroAid) as a traditional Chinese medicine on motor recovery after ischemic stroke. Methods. This study was a double‐blind, placebo‐controlled clinical trial on 150 patients with a recent (less than 1 month) ischemic stroke. All patients were given either MLC601 (100 patients) or placebo (50
A. A. Harandi   +11 more
wiley   +1 more source

The potential of MLC901 as adjuvant therapy for traumatic spinal cord injury by multi-pathway biomechanism: a systematic review

open access: yesBali Medical Journal, 2023
Background: Traumatic spinal cord injury (tSCI) is a severe neurological condition that causes long-term nerve function impairment and can even cause death. Further efforts are needed to find better therapy for this condition to improve patients' quality and life expectancy.
Dewa Putu Wisnu Wardhana   +7 more
openaire   +1 more source

MLC901, a Traditional Chinese Medicine induces neuroprotective and neuroregenerative benefits after traumatic brain injury in rats

open access: yesNeuroscience, 2014
Traumatic brain injury (TBI) is a frequent and clinically highly heterogeneous neurological disorder with large socioeconomic consequences. NeuroAid (MLC601 and MLC901), a Traditional Medicine used in China for patients after stroke has been previously reported to induce neuroprotection and neuroplasticity.
Quintard, H.   +4 more
openaire   +2 more sources

Home - About - Disclaimer - Privacy